Financial Performance Highlights

Q2 FY27 vs Q2 FY26 (YoY Comparison):

  • Revenue from operations: INR 288.4 crore (vs INR 230.4 crore) - 25.2% increase
  • EBITDA: INR 49.7 crore (vs INR 37.9 crore) - 31.1% increase
  • EBITDA margin: 17.23% (vs 16.45%)
  • Profit before tax: INR 31.5 crore (vs INR 20.5 crore) - 53.7% increase
  • PBT margin: 10.95% (vs 8.89%)
  • Profit after tax: INR 23.5 crore (vs INR 14.9 crore) - 57.7% increase
  • PAT margin: 8.15% (vs 6.47%)

H1 FY27 vs H1 FY26 (Half-yearly Comparison):

  • Revenue from operations: INR 549.2 crore (vs INR 457.3 crore) - 20.1% increase
  • EBITDA: INR 96.9 crore (vs INR 71.1 crore) - 36.3% increase
  • EBITDA margin: 17.64% (vs 15.55%)
  • Profit before tax: INR 61.7 crore (vs INR 36.8 crore) - 67.7% increase
  • Profit after tax: INR 46.0 crore (vs INR 27.0 crore) - 70.4% increase
  • PAT margin: 8.38% (vs 5.90%)

Regulatory Updates - Indore Plant

  • US FDA completed pre-approval inspection with 3 observations (non-critical) - team addressing within stipulated timeframe
  • EU GMP compliance report submitted - awaiting certification
  • Hosted audits from prospective US and UK market partners
  • Plant registered with US FDA and first product dossier filed
  • Targeting US market entry by Q2/Q3 2028 and Europe entry by September 2027

Business Segment Performance

International Business:

  • Received 3 registrations in Saudi Arabia with first orders
  • First commercial order in Chile through partner
  • First order for antifungals in UK and Germany
  • Entered Italy through partner and extended distribution to 5 European countries via Gufic Ireland
  • Targeting 156-182 marketing authorizations across 22-24 countries

Domestic Business - Hospital Injectables:

  • AWABAC (launched June) established across corporate, tertiary, and secondary care hospitals
  • Anti-infective franchise continued growth with improved position in key antifungal classes
  • Sparsh division: company-manufactured brands now majority of business
  • Dual-chamber bag gaining acceptance at leading institutions
  • Pilot program for smaller nursing homes in Mumbai initiated

Women's Health:

  • Ferticare leading in recurrent implantation failure with Guficin Alpha
  • Research article published and clinical practice recommendations released
  • Puregraf group deepened presence in corporate IVF chains
  • Cetrocare introduced in prefilled syringe format

Aesthetics & Therapeutics:

  • Stunnox (botulinum toxin) completed 5 years in market - second-largest brand in segment
  • Consensus recommendation on dosing in Indian patients published
  • Three clinical studies initiated
  • Dermal filler range from Canadian partners in preparation
  • NeuroCare growing in core indications and extending to adjacent specialties

Healthcare Division:

  • Sallaki range continued growth - leadership in Boswellia serrata segment
  • Gufican Oil fastest-growing brand in division
  • Napro Pure launched - first step into allopathic pain management

Operational Updates

  • Depot suite ready for trials and media fills
  • Spray-dried route for lipid-based antifungal near completion
  • Injectable emulsion format moved through scaleup
  • Output across all four production lines higher than Q1
  • R&D focus on peptides, API self-reliance, and novel drug delivery systems
  • 17 active and pipeline clinical studies ongoing

Financial Position & Guidance

  • Gross margin dipped due to rupee devaluation affecting API import prices and increased transportation costs
  • Inventory increased to INR 370 crore (from normal ~INR 325-330 crore) due to geopolitical concerns and validation batches for regulated markets
  • Debt increased due to working capital requirements and inventory buildup
  • Capex of INR 20-30 crore annually financed through internal accruals
  • Semaglutide investment of INR 22-25 crore expected to yield returns from Q1/Q2 next year
  • Target: 15-20% annual revenue growth
  • EBITDA margin target: 22-25% over medium term with 1% annual improvement

Management Commentary

  • Indore plant currently at EBITDA breakeven, expected to cover depreciation and interest by Q4 FY27
  • International revenue mix: 65-70% from regulated markets (Europe, South Africa, Brazil, Colombia, UK)
  • Botulinum toxin revenue: ~$3.5-3.6 million annually, targeting 25-30% growth
  • Domestic business growth: ~12% annually
  • International business growth: ~20-22% annually
  • CMO business growth: ~4-5% annually

Future Outlook

  • Expect margin normalization by Q4 FY27
  • Planning 4-6 additional molecules at Indore between November 2026-March 2027
  • Targeting 10-15% market share in addressable market of INR 824 million across 22-24 countries
  • Next phase of international investment to focus on botulinum toxin, depot, and liposomal products
  • Continuing evolution into complex products including once-in-a-week antibiotics, depots, liposomal products, and recombinant molecules